Physician profile
Rohit Malik
NPI 1396944039
$4,898.28
in general payments reported to CMS, 2019-2025
35 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $226 · 2021: $108 · 2022: $330 · 2023: $864 · 2024: $1,162 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,921.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,419.48 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,281.73 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $221.59 | 2023-2025 | Dupixent |
| Genzyme Corporation | $199.68 | 2019-2025 | |
| Harmony Biosciences LLC | $184.99 | 2023-2025 | Wakix |
| Verona Pharma, INC. | $147.65 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $126.46 | 2019-2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $107.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.91 | 2023-2025 | Ofev, Jascayd |
| Philips North America LLC | $101.95 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $95.09 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $90.09 | 2020-2025 | Aralast |
| Mylan Specialty L.P. | $81.73 | 2023-2024 | Yupelri |
| Genentech USA, INC. | $74.54 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $72.97 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $71.54 | 2024-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $63.34 | 2024-2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $54.37 | 2023-2025 | Sunosi |
| Lilly USA, LLC | $51.65 | 2025 | Zepbound |
| Novo Nordisk INC | $34.55 | 2024-2025 | Wegovy |
| Inspire Medical Systems, INC. | $33.76 | 2024 | Inspire |
| United Therapeutics Corporation | $33.06 | 2023-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $29.80 | 2019-2025 | |
| Insmed, INC. | $29.11 | 2023 | Arikayce |
| Edwards Lifesciences Corporation | $25.21 | 2023 | |
| Sequel Med Tech, LLC | $21.24 | 2025 | Twiist |
| Covis Pharma Gmbh | $18.51 | 2022 | |
| Abbvie INC. | $18.06 | 2025 | |
| Resmed Corp | $17.34 | 2020 | |
| Nabriva Therapeutics, Plc | $17.11 | 2020 | |
| Electromed, INC. | $15.31 | 2025 | Smartvest |
| Viatris Specialty LLC | $15.00 | 2025 | Yupelri |
| Hikma Pharmaceuticals USA | $14.11 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $13.54 | 2023 | Belsomra |
| Circassia INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.